Clinical Trials Browser

Interventional × IDO-1 inhibitor LY3381916 × Clear all

NCT03343613 2020-06-09

A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors

Phase 1 Terminated

BreastGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms

NCT01822691 2016-01-18

Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)

Phase 2 Completed

15 enrolled 8 charts

Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute